Hello, everyone, and how are you today? We are doing just fine, thank you, now that the biopharma Woodstock is winding down and our series of daily back-to-back meetings will soon come to end. This calls for a celebratory cup of stimulation, which yields a bit of an adventure in the City by the Bay, since the choices are endless. Such problems, yes? Meanwhile, here are some items of interest. Hope you have a smashing day and do stay in touch …

Endo Pharmaceuticals (ENDO) received a grand jury subpoena from the feds seeking documents relating to drugs containing oxymorphone. The subpoena seeks records produced in past or pending lawsuits and others relating to safety and efficacy; overdoses; diversion; theft; overprescribing; abuse; misuse; dependency; withdrawal; addiction, and adverse events. The feds also want distribution and third-party agreements; sales and marketing, training, financial, compensation and corporate information; and documents relating to interactions with government agencies.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy